2025-06-05 Grand Pharma’s Global Innovative Ophthalmic Drug CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial

2025-05-30 Grand Pharma’s Global Innovative Product for the Treatment of Demodex Blepharitis Is Approved for Commercialization by Macao ISAF of China

2025-03-01 Update on Strategic Investment in Telix

2025-04-22 The Clinical Study in China of the Global Innovative RDC GPN02006 Achieved a Milestone Breakthrough

2025-05-06 2024 Grand Pharma Annual Report

2025-05-07 The Phase II Clinical Study in China of the Global Innovative Product STC3141 Successfully Reached the Clinical Endpoint

2025-05-08 The Application for the Global Innovative RDC TLX591 to Join International Multicenter Phase III Clinical Trial Is Accepted by the NMPA

2025-05-23 Grand Pharma’s World First Closed-loop Platform Nuclear Medicine R&D And Production Base Is about To Be Put Into Operation

2025-01-03 The Registration Clinical Study Conducted in China of the Global Innovative Temperature-Sensitive Embolic Agent Has Completed the First Patient Enrollment

2024-12-31 Grand Pharma’s Cardiovascular and Cerebrovascular Precision Interventional Diagnostics Segment Receives Approvals for Three Major Products

2024-12-30 Grand Pharma Fuchi Industrial Park Successfully Evaluated as Class D Park, Opening a New Chapter of Safety Development

2024-12-17 NDA for a Global Innovative Product of the Group Treated for Demodex Blepharitis Has Been Accepted by NMPA